Issue Archive
March 2007 | Volume 6 | Issue 3
Original Articles
Outcomes Associated with the Use of Biologic Agents in Moderate to Severe Psoriasis
An estimated 2.1% of Americans have psoriasis and approximately 30% of them have moderate to severe psoriasis. Although the disease is not associated with mortality, it has a significant impact on he...
Read MoreIdentification of Novel Hsp65 RFLPs for Mycobacterium Leprae
Leprosy or Hansen’s disease is a chronic infectious disease caused by an acid-fast bacillus, Mycobacterium leprae (M. leprae). The bacilli proliferate in macrophages infiltrating the skin and ...
Read MoreXeroderma Pigmentosum: Beyond Skin Cancer
Xeroderma pigmentosum (XP) is a rare, autosomal-recessive inherited disease that is found worldwide at a frequency of approximately 1:250,000. XP is caused by a deficiency in either nucleotide excisi...
Read MoreOptimization of Narrow-Band UVB with a 5% Oleic Acid Cream in the Treatment of Psoriasis
Oleic acid is a monounsaturated fatty acid with a known action of penetration enhancer which has been used for various purposes, such as a tanning increaser. Narrow-band ultraviolet B (UVB) is a also...
Read MoreColloid Milium: A Review and Update
Colloid milium (CM) is a rare cutaneous deposition disease with at least 3 distinct subtypes. The exact histogenesis of the condition is still unresolved and awaits definitive elucidation. Electron m...
Read MoreReductions in Healthcare Resource Utilization in Psoriatic Arthritis Patients Receiving Etanercept Therapy: Results from the EDUCATE Trial
The Experience Diagnosing, Understanding Care, and Treatment with Enbrel® (EDUCATE) trial is a phase IV, 24-week, multicenter, open-label study of etanercept 50 mg weekly in the treatment of psori...
Read MoreA Single-Center, Open-Label, Prospective Pilot Study of Subcutaneous Efalizumab for Oral Erosive Lichen Planus
Objective: To evaluate the efficacy of efalizumab in the treatment of oral erosive lichen planus. Design: A single-center, open-label, prospective pilot study. The primary efficacy outcome measure wa...
Read MoreTreatment of Moderate to Severe Inflammatory Acne Vulgaris: Photodynamic Therapy with 5-Aminolevulinic Acid and a Novel Advanced Fluorescence Technology Pulsed Light Source
The use of photodynamic therapy (PDT) with 20% 5-aminolevulinic acid (ALA) for the treatment of acne vulgaris has been explored. This study evaluates the safety and efficacy of a new Advanced Fluores...
Read More
Features
Case Reports
Delayed Presentation of Impending Necrosis following Soft Tissue Augmentation with Hyaluronic Acid and Successful Management with Hyaluronidase
Soft tissue augmentation is a key element in the successful management of facial rhytids and scars. Injection of hyaluronic acid gels into the dermis is generally well-tolerated with only minimal sid...
Read MoreEosinophilic Granuloma of the Skin: Response to Intralesional Corticosteroid Injection
Langerhans cell histiocytosis (LCH) is a histiocytic disorder in which the Langerhans cell is arrested in a premature, partially active state. The disease comprises a spectrum of disorders, the most ...
Read MorePersistent Erythema Multiforme and CMV Infection
Persistent erythema multiforme is a rare disorder with only 23 known cases reported in the literature. Persistent erythema multiforme has been reported in association with Epstein-Barr virus, herpes ...
Read MoreClinical Improvement of Pityriasis Rubra Pilaris with Efalizumab in a Pediatric Patient
Pityriasis rubra pilaris has no single effective therapy and there are some cases resistant to multiple treatments. Psoriasis has clinical and therapeutic response overlaps with pityriasis rubra pila...
Read MoreTreatment of Pityriasis Rubra Pilaris with Pimecrolimus Cream 1%
Pityriasis rubra pillaris is an uncommon idiopathic dermatosis considered both a keratinization and an inflammatory disorder. Treatment is largely based on the information presented in case reports. ...
Read More
